GlassScriptPhysician profile
Yasir Cheema
NPI 1952515876
$3,169.70
in general payments reported to CMS, 2019-2025
16 companies · $2,543 in 2025
The $2,543 reported for 2025 was more than what 80% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $30.28 · 2021: $52.13 · 2022: $62.95 · 2023: $88.78 · 2024: $121 · 2025: $2,543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,502 · Food and Beverage: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,502.36 |
| Food and Beverage | $250.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $2,138.87 | 2025 | |
| Intuitive Surgical, INC. | $388.03 | 2025 | |
| Mylan Specialty L.P. | $150.12 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $131.74 | 2023-2024 | Dupixent |
| Glaxosmithkline, LLC. | $103.03 | 2019-2025 | Nucala |
| Abbott Laboratories | $64.25 | 2019-2022 | |
| Philips North America LLC | $36.57 | 2019-2023 | |
| Medtronic, INC. | $29.01 | 2021 | |
| Genzyme Corporation | $27.80 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $23.12 | 2021 | |
| United Therapeutics Corporation | $18.34 | 2023 | Tyvaso |
| Circassia INC. | $14.92 | 2019 | |
| Inspire Medical Systems, INC. | $14.21 | 2023 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.82 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $11.89 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $3.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yasir Cheema listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.